key: cord-0011487-lg2n8brx
authors: Dimopoulos, George; Akova, Murat; Rello, Jordi; Poulakou, Garyphalia
title: Understanding resistance in Pseudomonas
date: 2020-01-20
journal: Intensive Care Med
DOI: 10.1007/s00134-019-05905-6
sha: 8b3f1d65c9ad589930f6f80e01ff78501e4905f7
doc_id: 11487
cord_uid: lg2n8brx

nan

pending, murepavadin holds promise in the treatment of XDR strains (it was used as single antipseudomonal agent or combined with a standard antipseudomonal antibiotic). However, early in vitro reports revealed mutations indicative of a resistance mechanism shared with colistin, indicating that pre-existing colistin resistance involving lipopolysaccharide modifications could impede activity of murepavadin.

Alternatives to antimicrobial strategies, include new delivery methods (nebulization and encapsulation of antibiotics), vaccines-monoclonal antibodies (MA), and modulation of patient's immune response. Nebulization of antibiotics (mostly of colistin and aminoglycosides) has been used in heterogeneous dosage regimens and indications, ranging from ventilation-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) to colonization by resistant P. aeruginosa strains. Their use is hampered by the lack of standardization and broad experience [12] . The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) suggests the administration of antibiotics by aerosolisation in mechanically ventilated adults as a practice restricted to salvage therapy in VAP by difficult-to-treat organisms under a strict protocol of administration [13] . New delivery methods such as encapsulation of antibiotics in nanocarriers improve the drug diffusion, protect the drug from undesired degradation, control drug release, and increase uptake in the infected site [14] . These methods use anionic liposomes (with positive results in a model of pneumonia caused by P. aeruginosa in the absence of any additional antibiotic treatment), polyacid nanoparticles, water-soluble oligosaccharide conjugates, polymeric nanocomposites, or solid lipid nanoparticles. Ciprofloxacin, meropenem, and aminoglycosides have already been encapsulated into liposomes or loaded into nanoparticles [14] .

Therapeutic approaches through modulation of patient's response or the pathogenicity of P. aeruginosa are quite promising. The vaccine IC43, a recombinant *Correspondence: gdimop@med.uoa.gr outer membrane protein (Opr) targeting the Oprs of P. aeruginosa, completed a phase II trial, in which no significant difference was found in P. aeruginosa infection rates, although it was associated with a lower mortality rate [14] . Despite evident immunogenicity between days 7 and 14, P. aeruginosa infection occurred prior to the development of IgG immune response. ExoU is the most important virulence mechanism with impact on outcomes, although research efforts have been focused in blocking PcrV [14] . KB001, a pegylated anti-PcrV MA fragment to the type III secretion system (TTSS) of P. aeruginosa involved with the release of exotoxins, failed to show improvement in lung inflammation and reduction in colonization in patients with cystic fibrosis [14] . Other MAs include IgY avian polyclonal antibody (phase III clinical trial-NCT01455675 completed-results pending) and MEDI3902 binding to PcrV and Psl-mediating cytotoxicity (in phase II trial NCT02696902 in mechanically ventilated patients as of writing of this review) [14] . Modulators of bacterial cell wall, transport, signaling, or virulence have also been used against Pseudomonas spp. infections. Inhibitors of quorum sensing have demonstrated activity against biofilm formation and secretion of virulence factors (elastase-Las, rhamnolipids-Rhl, and Pseudomonas quinolone signal systems-PQS) [14] . However, until now, none of them has been evaluated in clinical practice. In the ICU, only macrolides were associated with a trend to prevent VAP and reduction of quorum sensing-regulated virulence factors activation [14] . Neutralization of virulence effectors inhibit P. aeruginosa LasB elastase targeting the ability of bacteria to evade the immune system, while Gallium, an iron mimetic, inhibits in vitro P. aeruginosa growth and biofilm formation [14] . Bacteriophages prevent damage to normal flora, do not infect the eukaryotic cells, and are not associated with rapid proliferation inside the host bacteria. The use of monophage vs cocktail treatment, the genomic identification (to minimize the risk of horizontal gene transfer to bacteria), and stability to reach the site of infection remain important challenges for the future [14] .

An antagonistic interaction to the yeast between Candida spp. and Pseudomonas aeruginosa and the role of cell wall components, quorum sensing molecules, phenazines, fatty acid metabolites, and competition for iron are well described [15] . The role of newly identified elements of P. aeruginosa QS network, oxylipin production by both species, as well as the genetic and phenotypic plasticity of those pathogens reflect suggested future perspectives. The prevention of P. aeruginosa resistance deals with microbiological monitoring, antimicrobial stewardship, and infection control programs (environmental cleaning/ disinfection, hand hygiene, and education of personnel), while the discrimination between colonization and infection is crucial (supplementary text).

In-depth understanding of the pathogenicity and resistance mechanisms of P. aeruginosa and its interactions with the host led to the development of several nonantibiotic approaches. Future treatments of P. aeruginosa infections, particularly by XDR strains, will probably adopt the aforementioned advancements with or without the addition of antibiotics.

Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa

Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN

Fitness cost of antibiotic susceptibility during bacterial infection

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology

Epidemiology and treatment of multi-drug resistant and extensively-drug resistant Pseudomonas aeruginosa infections

Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections

An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance

Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy

The "old" and the "new" antibiotics for MDR gram-negative pathogens: for whom, when, and how

Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

Mutations in pmrB confer cross-resistance between the LptD Inhibitor POL7080 and colistin in Pseudomonas aeruginosa

Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines

Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients

Emerging therapies against infections with Pseudomonas aeruginosa. F1000 Res 8(F1000 Faculty Rev

Beyond antagonism: the interaction between Candida species and Pseudomonas aeruginosa